Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.70 USD
Change Today -0.90 / -7.14%
Volume 100.0
INNL On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 10:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

innocoll ag-spon adr (INNL) Snapshot

Open
$11.70
Previous Close
$12.60
Day High
$11.70
Day Low
$11.70
52 Week High
06/12/15 - $16.46
52 Week Low
10/14/14 - $4.45
Market Cap
255.1M
Average Volume 10 Days
2.4K
EPS TTM
$-4.19
Shares Outstanding
21.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNOCOLL AG-SPON ADR (INNL)

Related News

No related news articles were found.

innocoll ag-spon adr (INNL) Related Businessweek News

No Related Businessweek News Found

innocoll ag-spon adr (INNL) Details

Innocoll AG, a specialty pharmaceutical company, manufactures and sells collagen-based pharmaceutical products and devices in Europe, the Middle East, Asia, and the United States. The company’s products comprise CollaGUARD, a transparent bioresorbable collagen film for the prevention of post-operative adhesions in various surgical applications, including digestive, colorectal, gynecological, and urological surgeries in open and laparoscopic approaches; Collatamp Gentamicin surgical implant for the treatment or prevention of post-operative infection; Septocoll, a bioresorbable dual-action collagen sponge for the treatment or prevention of post-operative infection; and RegenePro, a bioresorbable collagen sponge for dental applications. Its products also include XaraColl, an implantable and bioresorbable collagen sponge that is in phase III clinical trials for the treatment of post-operative pain relief; and Cogenzia, a topically applied bioresorbable collagen sponge, which is in phase III efficacy trials for the treatment of diabetic foot infections. The company is headquartered in Athlone, Ireland.

83 Employees
Last Reported Date: 04/23/15

innocoll ag-spon adr (INNL) Top Compensated Officers

Chairperson of The Management Board and Chief...
Total Annual Compensation: $32.4K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: $464.6K
Head of Portfolio Operations
Total Annual Compensation: $619.8K
Compensation as of Fiscal Year 2014.

innocoll ag-spon adr (INNL) Key Developments

Innocoll AG Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Innocoll AG announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of EUR 569,000 against EUR 1,316,000 a year ago. Loss from operating activities – continuing operations was EUR 8,585,000 against EUR 3,342,000 a year ago. Loss before income tax was EUR 24,717,000 against EUR 13,884,000 a year ago. Loss for the period attributable to equity holders of the company was EUR 24,741,000 against EUR 13,950,000 a year ago. Basic and diluted loss per share was EUR 15 against EUR 79.2 a year ago. Basic and diluted loss per ADS share was EUR 1.1 against EUR 6 a year ago. Non-GAAP net loss was EUR 9,804,000 against EUR 3,560,000 a year ago. Non-GAAP basic and diluted loss per share was EUR 5.9 against EUR 20.2 a year ago. Non-GAAP basic and diluted loss per ADS share was EUR 0.5 against EUR 1.5 a year ago. This decrease was primarily due to a decrease in sales to Jazz Pharmaceuticals/EUSA Pharma of CollatampG, gentamicin implant for the treatment and prevention of post-surgical infection, following Jazz Pharmaceuticals' sale of its EUSA Pharma division in March 2015. For the six months, the company reported revenue of EUR 1,185,000 against EUR 2,601,000 a year ago. Loss from operating activities – continuing operations was EUR 18,911,000 against EUR 16,902,000 a year ago. Loss before income tax was EUR 33,669,000 against EUR 30,092,000 a year ago. Loss for the period attributable to equity holders of the company was EUR 33,731,000 against EUR 30,147,000 a year ago. Basic and diluted loss per share was EUR 21.4 against EUR 19.1 a year ago. Basic and diluted loss per ADS share was EUR 1.6 against EUR 1.4 a year ago. Non-GAAP net loss was EUR 13,229,000 against EUR 11,824,000 a year ago. Non-GAAP basic and diluted loss per share was EUR 8.4 against EUR 1.5 a year ago. Non-GAAP basic and diluted loss per ADS share was EUR 0.6 against EUR 0.6 a year ago. Net cash used in operating activities was EUR 16,356,000 against EUR 3,471,000 a year ago. Purchases of property, plant and equipment was EUR 756,000 against EUR 293,000 a year ago.

Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development Effective August 20, 2015

Innocoll AG announced that Rich Fante has been appointed Chief Commercial Officer and Head of Business Development effective August 20, 2015. Mr. Fante has deep experience in the management and execution of commercial product strategies in the pharmaceutical industry. Most recently, he was founder and president of RF Consulting. Mr. Fante is currently a non-executive director of Inhibikase Therapeutics Inc.

Innocoll AG, Q2 2015 Earnings Call, Aug 14, 2015

Innocoll AG, Q2 2015 Earnings Call, Aug 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNL:US $11.70 USD -0.90

INNL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $38.55 USD -0.04
Durect Corp $2.04 USD +0.02
Sanofi €87.78 EUR -0.78
View Industry Companies
 

Industry Analysis

INNL

Industry Average

Valuation INNL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.5x
Price/Book 12.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 72.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOCOLL AG-SPON ADR, please visit www.innocollinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.